Cargando…
Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply
| Formato: | Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2000
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363191/ http://dx.doi.org/10.1054/bjoc.1999.0952 |
| _version_ | 1782153642509336576 |
|---|---|
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2363191 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2000 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-23631912009-09-10 Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply Br J Cancer Letter to the Editor Nature Publishing Group 2000-01 1999-12-08 /pmc/articles/PMC2363191/ http://dx.doi.org/10.1054/bjoc.1999.0952 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply |
| title | Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply |
| title_full | Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply |
| title_fullStr | Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply |
| title_full_unstemmed | Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply |
| title_short | Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply |
| title_sort | survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363191/ http://dx.doi.org/10.1054/bjoc.1999.0952 |